Johnson & Johnson (Janssen Biotech Inc.) / Legend Biotech Corporation
2017 · Co-Development · $9.0B · Complete
Announcement Sentiment
100
Strongly positive
Outcome Score
96
Worked — the deal delivered on its rationale.
Janssen Biotech (J&J subsidiary) entered an exclusive worldwide collaboration and license agreement with Legend Biotech to develop, manufacture, and commercialize ciltacabtagene autoleucel (cilta-cel, later branded CARVYKTI), a BCMA-directed CAR-T cell therapy for multiple myeloma. J&J paid $350 million upfront with additional milestone payments. The collaboration features a 50:50 cost and profit-sharing structure globally, except in Greater China (70% Legend / 30% Janssen). CARVYKTI received FDA approval in February 2022.